Cyclomethicone 50% / Isopropyl myristate 50% solution
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Full Marks brand family (generic: Cyclomethicone + Isopropyl myristate)
MHRA licensed products
View all licensed products for Cyclomethicone + Isopropyl myristate on the MHRA register
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
1987–2026
Showing the 50 most relevant studies, sorted by most relevant.
F. Podlogar, M. Gašperlin, Matija Tomšič, et al.
International journal of pharmaceutics, 2004
A. Arellano, Susana Santoyo, C. Martín, et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 1999
Yun Mo, L. Lim
Journal of controlled release : official journal of the Controlled Release Society, 2005
R. Aboofazeli, M. Lawrence
International Journal of Pharmaceutics, 1993
I. Alberti, Y. Kalia, A. Naik, et al.
International journal of pharmaceutics, 2001
Nur Çebi, O. Taylan, Mona Abusurrah, et al.
Foods, 2020
Essential oils are high-valued natural extracts that are involved in industries such as food, cosmetics, and pharmaceutics. The lemon essential oil (LEO) has high economic importance in the food and beverage industry because of its health-beneficial characteristics and desired flavor properties. LEO, similar to other natural extracts, is prone to being adulterated through economic motivations. Adulteration causes unfair competition between vendors, disruptions in national economies, and crucial risks for consumers worldwide. There is a need for cost-effective, rapid, reliable, robust, and eco-friendly analytical techniques to detect adulterants in essential oils. The current research developed chemometric models for the quantification of three adulterants (orange essential oil, benzyl alcohol, and isopropyl myristate) in cold-pressed LEOs by using hierarchical cluster analysis (HCA), principal component regression (PCR), and partial least squares regression (PLSR) based on FTIR spectra. The cold-pressed LEO was successfully distinguished from adulterants by robust HCA. PLSR and PCR showed high accuracy with high R2 values (0.99–1) and low standard error of cross-validation (SECV) values (0.58 and 5.21) for cross-validation results of the raw, first derivative, and second derivative FTIR spectra. The findings showed that FTIR spectroscopy combined with multivariate analyses has a considerable capability to detect and quantify adulterants in lemon essential oil.
Abstract licence: CC BY 4.0
M. Changez, M. Varshney, J. Chander, et al.
Colloids and surfaces. B, Biointerfaces, 2006
Keren Delmar, H. Bianco‐Peled
International journal of biological macromolecules, 2025
This study investigates the hypothesis that modified shellac nanoparticles (NPs) can effectively stabilize Pickering emulsions. Shellac, a natural polyester resin derived from the secretion of insects, was chemically modified using Jeffamine® M600 and Jeffamine® ED2003 to produce two NP types: Sh-M600 and Sh-ED2003, with sizes ranging from 127 to 183 nm. These NPs were used to stabilize oil-in-water emulsions with isopropyl myristate (IPM). Stability tests revealed that Sh-M600-stabzlized emulsions (up to 40 % oil) remained stable for 6 months, while Sh-ED2003-stabilized emulsions were stable with up to 65 % oil content, even under accelerated conditions. Cryo-SEM imaging confirmed NP accumulation at the oil-water interface, corroborated by reduced interfacial tension in the presence of NP. Adsorption energy calculations demonstrated the superior stabilization capacity of Sh-ED2003 NPs over Sh-M600 NPs. Rheological analysis further supported these findings, showing consistently higher viscosity viscosities for Sh-ED2003-stabilized emulsions across all oil percentages, attributed to the higher molecular weight of its modifier. Collectively, this study demonstrates the effectiveness of tailored shellac NPs in stabilizing robust emulsions, offering potential applications in food, pharmaceuticals, and agriculture.
Abstract licence: CC BY-NC-ND
Ming Song, Yuhan Xin, Sulan Cai, et al.
Catalysts, 2023
Free enzymes often face economic problems because of their non-repeatability and variability, which limit their application in industrial production. In this study, KDN lipase was immobilized with the macroporous resin LXTE-1000 and glutaraldehyde. The optimal conditions of enzyme immobilization were defined by a single factor experiment and response surface methodology (RSM). The concentration of the cross-linking agent glutaraldehyde was 0.46% (v/v), the cross-linking temperature was 25.0 °C, and the cross-linking time was 157 min. The enzyme activity of the immobilized KDN lipase after adsorption/cross-linking was 291.36 U/g, and the recovery of the enzyme activity was 9.90%. The optimal conditions for the synthesis of isopropyl myristate were catalyzed by the immobilized KDN lipase in a solvent-free system: immobilized enzyme 53 mg, reaction temperature 36.1 °C, myristic acid 228.4 mg, isopropanol 114 µL, and reaction time 18 h. The yield of isopropyl myristate was 66.62%. After ten cycles, the activity of the immobilized KDN lipase preserved more than 46.87% of its initial enzyme activity, and it demonstrated high tolerance to solvents compared to free KDN lipase.
Abstract licence: CC BY 4.0
A. Eichner, Sören Stahlberg, Stefan Sonnenberger, et al.
Biochimica et biophysica acta. Biomembranes, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.